Russia Claims Its Second COVID-19 Vaccine Is 100% Effective
Russia's consumer health watchdog Rospotrebnadzor claimed that the country's new COVID-19 vaccine, EpiVacCorona, is 100 percent effective following clinical trials, Reuters reports.
The news, originally reported via Russia's state-owned TASS news agency, appears to be a boost for Russia's COVID-19 vaccination campaign, which is already seeing the rollout of its first iteration, the Sputnik V vaccine.
Russia's COVID-19 vaccine rollout
Russia began mass trials of the new EpiVacCorona as recently as November. Developed by Siberia's Vector Institute, the vaccine is set to be the second approved by Moscow after Sputnik V.
Interim reports say that the Sputnik V vaccine is reportedly 92 percent effective at protecting people from COVID-19.
Though Sputnik V has a high efficacy rate, the trails didn't go completely smoothly, as 20 volunteers are said to have contracted COVID-19 during the process.
It remains to be seen whether the Russian government will opt to focus the majority of its efforts on rolling out EpiVaCorona with its higher efficacy rate, or whether it will focus on a speedier rollout by increasing the rate of vaccinations via increased supplies of both vaccines.
Comparing COVID-19 vaccines
Russia's Sputnik V and EpiVaCorona vaccines are, of course, not the only vaccines that are being administered to populations worldwide.
The Pfizer-BioNTech COVID-19 vaccine, developed in a collaboration between scientists from Germany and the U.S., was granted emergency use authorization on December 11. In Phase III trials, it demonstrated 95 percent efficacy. This vaccine must be stored at -94 degrees F (-70 degrees C), which requires specialized freezer units.
The Moderna vaccine, developed by an American pharmaceutical and biotechnology company, was authorized by the FDA on December 19. It is reported to have an efficacy rate of 94.5 percent.
The AstraZeneca and the University of Oxford vaccine showed preliminary results suggesting it was up to 90 percent effective, with the first dose reportedly giving 70 percent protection.
With a recent study stating that COVID-19 immunity likely last for years, the continued development and rollout of COVID-19 vaccines worldwide points towards a gradual easing of restrictions and a light at the end of the tunnel.
A chip company is building the brains of a self-driving experimental vehicle. What sets them apart from their competitors is their use of photonic or light-powered chips, unlike the others' traditional computer chips.